Insight

Hung Trinh: Bispecific Antibodies in Solid Tumors

Hung Trinh/LinkedIn

Jul 19, 2025, 00:34

Hung Trinh: Bispecific Antibodies in Solid Tumors

Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:

“Bispecific Antibodies in Solid Tumors: Advances and Challenges

Bispecific antibodies (BsAbs) have shown potential in cancer treatment and have become a rapidly growing field in cancer immunotherapy. Unlike monoclonal antibodies with two identical binding sites, BsAbs simultaneously bind two distinct epitopes on the same or different antigens, allowing for a range of mechanisms of action, including engaging immune cells to kill cancer cells and blocking signaling pathways. Despite regulatory approvals for hematological malignancies in the last decade, their clinical success in solid malignancies has been lacking until recently.

There are currently five BsAbs approved by the FDA in the United States for solid tumors—amivantamab, tarlatamab, tebentafusp, zanidatamab and zenocutuzumab—and two BsAbs approved in China—cadonilimab and ivonescimab. Currently, several BsAbs are under clinical development for solid tumors, but are mostly in early phase I and II trials. This review provides an overview of the basic mechanism of action of BsAbs, current FDA-approved BsAbs, and current BsAbs under clinical development, their challenges in clinical use, the management of toxicities, and future directions.

There are currently five BsAbs approved by the FDA in the United States for solid tumors—amivantamab, tarlatamab, tebentafusp, zanidatamab and zenocutuzumab—and two BsAbs approved in China—cadonilimab and ivonescimab. Currently, several BsAbs are under clinical development for solid tumors, but are mostly in early phase I and II trials. This review provides an overview of the basic mechanism of action of BsAbs, current FDA-approved BsAbs, and current BsAbs under clinical development, their challenges in clinical use, the management of toxicities, and future directions.”

Title: Bispecific Antibodies in Solid Tumors: Advances and Challenges

Authors: Khine Swe Shan, Saba Musleh Ud Din, Shivani Dalal, Teresita Gonzalez, Misha Dalal, Pablo Ferraro, Atif Hussein, Michel Vulfovich

Read the Full Article.

Hung Trinh

More posts featuring Hung Trinh.

Atif Hussein Bispecific antibodies cancer FDA Hung Trinh Khine Swe Shan Michel Vulfovich Misha Dalal OncoDaily Oncology Pablo Ferraro Saba Musleh Ud Din Shivani Dalal Teresita Gonzalez

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer